The KLKB1 gene gives your body instructions for making a blood protein that helps start signals involved in clotting, inflammation, and blood pressure control. This gene plays an important role in keeping these systems balanced. If the gene does not work properly, the activated partial thromboplastin time (aPTT, a blood clotting test) may be longer than expected, and some people have prekallikrein deficiency. Most people with this deficiency do not have unusual bleeding symptoms.
What is a gene?
Genes are stretches of DNA that provide cells with instructions they can use to make molecules or manage processes in the body. Some genes hold the information needed to produce proteins, the parts of cells that do much of the work. Other genes mostly help regulate when, where, and how strongly certain processes occur. Together, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medications. For a more in depth look at this topic, you can find more in the LearnHub.
Overview
KLKB1Gene function
What if the gene works
The KLKB1 gene helps your liver make prekallikrein, a blood protein. This protein helps control clotting, inflammation, and blood flow by supporting the release of bradykinin, a signal that relaxes blood vessels.
Risk
What if the gene does not work
Changes in the KLKB1 gene can cause prekallikrein deficiency, often causing a long blood clotting test result but little or no bleeding. Milder and severe variants can reduce protein activity to different degrees, so features may vary.
Treatment
What does that mean for your treatment
No treatment approach specific to pathogenic variants in the KLKB1 gene is currently established. Plasma kallikrein, the protein made from this gene, is being studied as a drug target in conditions involving swelling and inflammation, including hereditary angioedema, but that does not change care for KLKB1 deficiency itself.
Conditions associated with KLKB1
Gene function
What if the gene works
In daily life, the KLKB1 gene helps your blood respond in a coordinated way when tissues are disturbed. It makes a protein that takes part in normal blood clotting, inflammation, and blood vessel control. Understanding how the KLKB1 gene affects blood clotting and inflammation helps show why this pathway matters for routine healing and circulation.
The KLKB1 gene gives instructions for making prekallikrein, a protein that circulates in blood in a ready but inactive form. When activated, it becomes plasma kallikrein, an enzyme that helps coordinate several normal blood responses.
Plasma kallikrein helps release bradykinin, a small signal that tells blood vessels how to respond. This supports normal widening of blood vessels and the early inflammatory response after minor tissue stress.
Plasma kallikrein works closely with factor XII in the contact system, an early blood response pathway. Together they help connect normal clotting signals with inflammation and blood flow control.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and help explain normal differences between people, including appearance, metabolism, and the way the body reacts to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant can change how a gene works to a greater extent and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the KLKB1 gene can change how the blood protein prekallikrein is made, folded, or switched on, which helps explain how KLKB1 gene variants affect protein function. Milder variants may leave some protein activity or stability, while more severe variants can sharply reduce production, block activation to kallikrein, or make the protein break down sooner. In people with stronger loss of function variants, prekallikrein deficiency is more likely to be marked, and laboratory changes can be more pronounced.
How variants are linked to conditions
Pathogenic variants in the KLKB1 gene cause prekallikrein deficiency, a rare inherited condition also called Fletcher factor deficiency. In people reading about KLKB1 gene variants linked to conditions, this is the main well-established diagnosis. It is often discovered when a blood clotting test shows a longer activated partial thromboplastin time, or aPTT, than expected. Many people with this finding do not have unusual bleeding symptoms.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of human biology and are common throughout the general population. Most do not have a direct effect on health and instead reflect natural human variation. For many genes, carrying a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. In some situations, though, one well-characterized variant in a specific gene is enough to confirm the diagnosis.
Are there things that can increase or change my risk?
There isn't yet broadly confirmed evidence on specific factors that increase or reduce health risk related to the KLKB1 gene. Risk can vary depending on the exact gene change and the condition involved, so people with questions about their own risk should speak with a doctor or genetic counselor.
Inheritance of KLKB1 variants
Variants in the KLKB1 gene linked to prekallikrein deficiency are inherited in an autosomal recessive pattern. This means a person usually inherits one changed copy from each parent, while parents with one changed copy are typically carriers. When both parents carry a KLKB1 variant, each child has a 25% chance of inheriting both changed copies, a 50% chance of being a carrier, and a 25% chance of inheriting neither changed copy. In families asking how KLKB1 gene variants are inherited, sons and daughters are affected equally.
What does my KLKB1 result mean for my family?
For KLKB1, family implications are usually discussed in the context of prekallikrein deficiency, an inherited blood-clotting finding that often runs in families in a recessive pattern. This means siblings may also have the condition or be carriers, and other close relatives may be carriers without knowing it. Children of someone with a KLKB1 change are often carriers unless the other parent also carries a change in the same gene.
Genetic information
Genetic testing
How you find out about variants
KLKB1 genetic testing looks for variants in the KLKB1 gene using a blood sample or saliva. A lab reads the gene’s DNA sequence and compares it with the usual sequence to identify changes. Results can show whether you carry a variant linked to prekallikrein deficiency or whether no relevant variant was found.
When should I consider getting a genetic test?
You may consider KLKB1 genetic testing if you or a close relative has been found to have prekallikrein deficiency, or if blood clotting tests repeatedly take much longer than expected without a clear reason. Testing can help confirm whether a change in KLKB1 explains the result and whether it may run in the family.
A genetic result is only one part of your health story
Genetic test findings can provide useful insight, yet how much they explain varies with the condition and the kind of variant that is present. Over time, the way your body functions is shaped by many factors, including lifestyle, environment, age, and medical history. For some conditions, particularly those affected by many genes, genetic information offers context rather than certainty and makes the most sense when viewed together with the rest of a person’s care. In other situations, a genetic finding can give a clear answer. In areas like medication response, these results can also help frame individual experiences.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment works well for one person, has less effect in another, or causes more side effects in someone else. Small differences in how the body absorbs, breaks down, or responds to a drug are common, and they can influence both benefit and sensitivity.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in a person’s genes can affect their response to medicines. By looking at gene drug patterns, it helps explain why the same treatment may work differently from one person to another. For many medications, genes can influence both how strongly a drug works and how the body handles it. This information can support treatment decisions that are more informed and more individualized. You can read more about this topic in the LearnHub.
Drugs influenced by the KLKB1 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choices, so general health concerns, side effects, or questions about treatment changes are best discussed with your doctor.
History
KLKB1 entered medical research through studies of unusual blood clotting test results in the 1960s, when doctors described prekallikrein deficiency in families and in the well known “Fletcher factor” case. Initially understood only through visible traits, later recognized as tied to a specific gene, this work helped researchers separate different causes of prolonged clotting tests. From these first observations, research expanded steadily. By the 1980s and 1990s, scientists had identified and mapped the KLKB1 gene, linking earlier clinical findings to a clear genetic basis. That timeline made KLKB1 part of the broader story of how coagulation research moved from bedside observations to gene level diagnosis. Today, its history is mainly remembered within hematology and inherited bleeding research.